148 related articles for article (PubMed ID: 33676848)
21. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
22. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR.
Poremba C; Heine B; Diallo R; Heinecke A; Wai D; Schaefer KL; Braun Y; Schuck A; Lanvers C; Bànkfalvi A; Kneif S; Torhorst J; Zuber M; Köchli OR; Mross F; Dieterich H; Sauter G; Stein H; Fogt F; Boecker W
J Pathol; 2002 Oct; 198(2):181-9. PubMed ID: 12237877
[TBL] [Abstract][Full Text] [Related]
23. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
24. Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.
Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Siraj N; Siraj S; Diaz MRF; Rala DR; Benito AD; Sabido MA; Al-Rasheed M; Al-Obaisi KAS; Al-Haqawi W; Victoria IG; Al Balawy W; Abedalthagafi M; Wakil SM; Ajarim D; Mohammed S; Alhussain T; Tulbah A; Al-Badawi IA; Al-Dayel F; Al-Kuraya KS
Genomics; 2020 Mar; 112(2):1746-1753. PubMed ID: 31669704
[TBL] [Abstract][Full Text] [Related]
25. Telomerase inhibition strategies by siRNAs against either hTR or hTERT in oral squamous cell carcinoma.
Li Y; Li M; Yao G; Geng N; Xie Y; Feng Y; Zhang P; Kong X; Xue J; Cheng S; Zhou J; Xiao L
Cancer Gene Ther; 2011 May; 18(5):318-25. PubMed ID: 21233858
[TBL] [Abstract][Full Text] [Related]
26. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
27. Expression and biological-clinical significance of hTR, hTERT and CKS2 in washing fluids of patients with bladder cancer.
Mezzasoma L; Antognelli C; Del Buono C; Stracci F; Cottini E; Cochetti G; Talesa VN; Mearini E
BMC Urol; 2010 Oct; 10():17. PubMed ID: 20920335
[TBL] [Abstract][Full Text] [Related]
28. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ
Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487
[TBL] [Abstract][Full Text] [Related]
29. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
Hayashidani Y; Hiyama E; Murakami Y; Sueda T
Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
[TBL] [Abstract][Full Text] [Related]
30. Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma.
Bialkowska-Hobrzanska H; Bowles L; Bukala B; Joseph MG; Fletcher R; Razvi H
Mol Diagn; 2000 Dec; 5(4):267-77. PubMed ID: 11172490
[TBL] [Abstract][Full Text] [Related]
31. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
32. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
[TBL] [Abstract][Full Text] [Related]
33. Functional multimerization of human telomerase requires an RNA interaction domain in the N terminus of the catalytic subunit.
Moriarty TJ; Huard S; Dupuis S; Autexier C
Mol Cell Biol; 2002 Feb; 22(4):1253-65. PubMed ID: 11809815
[TBL] [Abstract][Full Text] [Related]
34. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.
Hosen MI; Sheikh M; Zvereva M; Scelo G; Forey N; Durand G; Voegele C; Poustchi H; Khoshnia M; Roshandel G; Sotoudeh M; Nikmanesh A; Etemadi A; Avogbe PH; Chopard P; Delhomme TM; Foll M; Manel A; Vian E; Weiderpass E; Kamangar F; Boffetta P; Pharaoh PD; Dawsey SM; Abnet CC; Brennan P; McKay J; Malekzadeh R; Calvez-Kelm FL
EBioMedicine; 2020 Mar; 53():102643. PubMed ID: 32081602
[TBL] [Abstract][Full Text] [Related]
35. Human telomerase reverse transcriptase binds to a pre-organized hTR in vivo exposing its template.
Zemora G; Handl S; Waldsich C
Nucleic Acids Res; 2016 Jan; 44(1):413-25. PubMed ID: 26481359
[TBL] [Abstract][Full Text] [Related]
36. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts.
Brems-Eskildsen AS; Zieger K; Toldbod H; Holcomb C; Higuchi R; Mansilla F; Munksgaard PP; Borre M; Ørntoft TF; Dyrskjøt L
BMC Cancer; 2010 Nov; 10():646. PubMed ID: 21106093
[TBL] [Abstract][Full Text] [Related]
37. Quantification of human telomerase RNA (hTR) and human telomerase reverse transcriptase (hTERT) mRNA in testicular tissue of infertile patients.
Schrader M; Müller M; Heicappell R; Straub B; Miller K
Asian J Androl; 2001 Dec; 3(4):263-70. PubMed ID: 11753470
[TBL] [Abstract][Full Text] [Related]
38. Activating Telomerase
Zvereva M; Pisarev E; Hosen I; Kisil O; Matskeplishvili S; Kubareva E; Kamalov D; Tivtikyan A; Manel A; Vian E; Kamalov A; Ecke T; Calvez-Kelm FL
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839402
[TBL] [Abstract][Full Text] [Related]
39. Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma.
Ako S; Nouso K; Kinugasa H; Matsushita H; Terasawa H; Adachi T; Wada N; Takeuchi Y; Mandai M; Onishi H; Ikeda F; Shiraha H; Takaki A; Fujioka S; Mimura T; Okada H
Oncology; 2020; 98(5):311-317. PubMed ID: 32135540
[TBL] [Abstract][Full Text] [Related]
40. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.
Wang K; Liu T; Liu L; Liu J; Liu C; Wang C; Ge N; Ren H; Yan K; Hu S; Björkholm M; Fan Y; Xu D
Oncotarget; 2014 Apr; 5(7):1829-36. PubMed ID: 24742867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
